
South Korea\'s anti-trust agency has fined drugmaker GlaxoSmithKline three billion won ($2.6 million) for conspiring with a Seoul rival over the sale of drugs, an official said Monday. The Fair Trade Commission (FTC) said GSK in 2000 offered Dong-A Pharmaceutical the exclusive right to sell its anti-nausea drug Zofran and an anti-viral medication called Valtrex. In return, the FTC said the British-based multinational demanded that Dong-A stop selling a cheaper generic version of Zofran which the Seoul firm had introduced in 1998. GSK also asked that Dong-A never produce or sell any drugs that could compete against Zofran and Valtrex, Kim Jun-Ha, a FTC official involved in the case, told AFP. \"With the cheaper generics made by Dong-A taken off the market, the financial burden on patients and on the government\'s health insurance budget has increased,\" Kim said. The FTC said in a statement it estimated GSK had made wrongful gains of about 16 billion won. It said \"the two firms shared benefits that were to go to consumers\". Dong-A was fined 2.1 billion won for the collusion, the agency added. GSK\'s South Korean unit called the decision \"very regrettable\" and \"inappropriate\" and said it would appeal in court. \"We simply exercised our legitimate patent rights,\" it said in a statement, adding that there was no illegality.
GMT 09:47 2018 Tuesday ,23 January
SAP unveils big push into French tech start-upsGMT 05:07 2018 Tuesday ,23 January
Noble Group shares surge 37 percent on buyout talksGMT 19:07 2018 Monday ,22 January
BAKS spent Dh225m on charity projects in 2017GMT 22:52 2018 Sunday ,21 January
French firm "recalls baby milk product"GMT 22:27 2018 Sunday ,21 January
US company plans funds that double bitcoin price movesGMT 21:23 2018 Sunday ,21 January
Pence starts Mideast tour in Egypt amid Arab angerGMT 08:54 2018 Saturday ,20 January
Million-euro bill for firm behind Paris bike-share chaosGMT 10:47 2018 Friday ,19 January
German chemical giant BASF sees 'significant' profit leap

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor